In vitro effects of topotecan and ionizing radiation on TRAIL/ Apo2L-mediated apoptosis in malignant glioma

Emilio Ciusani, Danilo Croci, Maurizio Gelati, Chiara Calatozzolo, Francesca Sciacca, Luisa Fumagalli, Marco Balzarotti, Laura Fariselli, Amerigo Boiardi, Andrea Salmaggi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The survival of patients with malignant gliomas is still unsatisfactory despite multimodality treatment, therefore new therapeutic strategies are required. Tumor necrosis factor apoptosis related ligand (TRAIL/ Apo2L), a member of the tumor necrosis factor superfamily, may induce apoptotic cell death in several tumors, but not in normal cells, upon binding with specific receptors. In the present study, the expression and function of TRAIL receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) has been investigated in five human glioma cell lines (U87, U138, U373, A172, SW1783) in ex vivo tumors and in primary cultures obtained from the tumors. Our data show that gliomas preferentially express TRAIL R2 and that treatment with topotecan, a topoisomerase I inhibitor, significantly up-regulates its expression as detected by flow cytometry and western blotting. Moreover, in most cases, treatment with topotecan resulted in an increased sensitivity to TRAIL-dependent apoptosis, although cyclohexymide had to be added to induce apoptosis. On glioma cell lines, the effects of irradiation on TRAIL receptors were also analysed. In our experimental conditions, irradiation with 2 Gy had a modest additive effect on TRAIL-dependent apoptosis and was not able to modulate TRAIL receptor expression.

Original languageEnglish
Pages (from-to)19-25
Number of pages7
JournalJournal of Neuro-Oncology
Volume71
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Topotecan
TNF-Related Apoptosis-Inducing Ligand Receptors
Ionizing Radiation
Glioma
Apoptosis
Tumor Necrosis Factor-alpha
Topoisomerase I Inhibitors
Cell Line
Neoplasms
Therapeutics
Flow Cytometry
Cell Death
Up-Regulation
Western Blotting
Ligands
Survival
In Vitro Techniques

Keywords

  • Apoptosis
  • Glioma
  • Radiation
  • Topotecan
  • TRAIL

ASJC Scopus subject areas

  • Cancer Research
  • Clinical Neurology
  • Oncology
  • Neuroscience(all)

Cite this

In vitro effects of topotecan and ionizing radiation on TRAIL/ Apo2L-mediated apoptosis in malignant glioma. / Ciusani, Emilio; Croci, Danilo; Gelati, Maurizio; Calatozzolo, Chiara; Sciacca, Francesca; Fumagalli, Luisa; Balzarotti, Marco; Fariselli, Laura; Boiardi, Amerigo; Salmaggi, Andrea.

In: Journal of Neuro-Oncology, Vol. 71, No. 1, 01.2005, p. 19-25.

Research output: Contribution to journalArticle

@article{6946fb79b46f4c39a032ef382351bbec,
title = "In vitro effects of topotecan and ionizing radiation on TRAIL/ Apo2L-mediated apoptosis in malignant glioma",
abstract = "The survival of patients with malignant gliomas is still unsatisfactory despite multimodality treatment, therefore new therapeutic strategies are required. Tumor necrosis factor apoptosis related ligand (TRAIL/ Apo2L), a member of the tumor necrosis factor superfamily, may induce apoptotic cell death in several tumors, but not in normal cells, upon binding with specific receptors. In the present study, the expression and function of TRAIL receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) has been investigated in five human glioma cell lines (U87, U138, U373, A172, SW1783) in ex vivo tumors and in primary cultures obtained from the tumors. Our data show that gliomas preferentially express TRAIL R2 and that treatment with topotecan, a topoisomerase I inhibitor, significantly up-regulates its expression as detected by flow cytometry and western blotting. Moreover, in most cases, treatment with topotecan resulted in an increased sensitivity to TRAIL-dependent apoptosis, although cyclohexymide had to be added to induce apoptosis. On glioma cell lines, the effects of irradiation on TRAIL receptors were also analysed. In our experimental conditions, irradiation with 2 Gy had a modest additive effect on TRAIL-dependent apoptosis and was not able to modulate TRAIL receptor expression.",
keywords = "Apoptosis, Glioma, Radiation, Topotecan, TRAIL",
author = "Emilio Ciusani and Danilo Croci and Maurizio Gelati and Chiara Calatozzolo and Francesca Sciacca and Luisa Fumagalli and Marco Balzarotti and Laura Fariselli and Amerigo Boiardi and Andrea Salmaggi",
year = "2005",
month = "1",
doi = "10.1007/s11060-004-9180-4",
language = "English",
volume = "71",
pages = "19--25",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - In vitro effects of topotecan and ionizing radiation on TRAIL/ Apo2L-mediated apoptosis in malignant glioma

AU - Ciusani, Emilio

AU - Croci, Danilo

AU - Gelati, Maurizio

AU - Calatozzolo, Chiara

AU - Sciacca, Francesca

AU - Fumagalli, Luisa

AU - Balzarotti, Marco

AU - Fariselli, Laura

AU - Boiardi, Amerigo

AU - Salmaggi, Andrea

PY - 2005/1

Y1 - 2005/1

N2 - The survival of patients with malignant gliomas is still unsatisfactory despite multimodality treatment, therefore new therapeutic strategies are required. Tumor necrosis factor apoptosis related ligand (TRAIL/ Apo2L), a member of the tumor necrosis factor superfamily, may induce apoptotic cell death in several tumors, but not in normal cells, upon binding with specific receptors. In the present study, the expression and function of TRAIL receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) has been investigated in five human glioma cell lines (U87, U138, U373, A172, SW1783) in ex vivo tumors and in primary cultures obtained from the tumors. Our data show that gliomas preferentially express TRAIL R2 and that treatment with topotecan, a topoisomerase I inhibitor, significantly up-regulates its expression as detected by flow cytometry and western blotting. Moreover, in most cases, treatment with topotecan resulted in an increased sensitivity to TRAIL-dependent apoptosis, although cyclohexymide had to be added to induce apoptosis. On glioma cell lines, the effects of irradiation on TRAIL receptors were also analysed. In our experimental conditions, irradiation with 2 Gy had a modest additive effect on TRAIL-dependent apoptosis and was not able to modulate TRAIL receptor expression.

AB - The survival of patients with malignant gliomas is still unsatisfactory despite multimodality treatment, therefore new therapeutic strategies are required. Tumor necrosis factor apoptosis related ligand (TRAIL/ Apo2L), a member of the tumor necrosis factor superfamily, may induce apoptotic cell death in several tumors, but not in normal cells, upon binding with specific receptors. In the present study, the expression and function of TRAIL receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) has been investigated in five human glioma cell lines (U87, U138, U373, A172, SW1783) in ex vivo tumors and in primary cultures obtained from the tumors. Our data show that gliomas preferentially express TRAIL R2 and that treatment with topotecan, a topoisomerase I inhibitor, significantly up-regulates its expression as detected by flow cytometry and western blotting. Moreover, in most cases, treatment with topotecan resulted in an increased sensitivity to TRAIL-dependent apoptosis, although cyclohexymide had to be added to induce apoptosis. On glioma cell lines, the effects of irradiation on TRAIL receptors were also analysed. In our experimental conditions, irradiation with 2 Gy had a modest additive effect on TRAIL-dependent apoptosis and was not able to modulate TRAIL receptor expression.

KW - Apoptosis

KW - Glioma

KW - Radiation

KW - Topotecan

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=14044267654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14044267654&partnerID=8YFLogxK

U2 - 10.1007/s11060-004-9180-4

DO - 10.1007/s11060-004-9180-4

M3 - Article

VL - 71

SP - 19

EP - 25

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -